nach oben

Clinical and Translational Oncology

Erschienen in:

05.08.2022 | Research Article

High levels of unfolded protein response component CHAC1 associates with cancer progression signatures in malignant breast cancer tissues

verfasst von: Vikrant Mehta, Prabhat Suman, Harish Chander

Erschienen in: Clinical and Translational Oncology | Ausgabe 12/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aberrant mRNA expression of a UPR component Cation transport regulator homolog 1 (CHAC1) has been reported to be associated with poor survival in breast and ovarian cancer patients, however, the expression of CHAC1 at protein levels in malignant breast tissues is underreported. The following study aimed at analyzing CHAC1 protein expression in malignant breast cancer tissues.

Methods

Evaluation of CHAC1 expression in invasive ductal carcinomas (IDCs) with known ER, PR, and HER2 status was carried out using immunohistochemistry (IHC) with CHAC1 specific antibody. The Human breast cancer tissue microarray (TMA, cat# BR1503f, US Biomax, Inc., Rockville, MD) was used to determine CHAC1 expression. The analysis of CHAC1 IHC was done to determine its expression in terms of molecular subtypes of breast cancer, lymph node status, and proliferation index using Qu-Path software. Survival analysis was studied with a Kaplan–Meier plotter.

Results

Immunohistochemical analysis of CHAC1 in breast cancer tissues showed significant up-regulation of CHAC1 as compared to the adjacent normal and benign tissues. Interestingly, CHAC1 immunostaining revealed high expression in tumor tissues with high proliferation and positive lymph node metastasis suggesting that CHAC1 might have an important role to play in breast cancer progression. Furthermore, high CHAC1 expression is associated with poor overall survival (OS) in large breast cancer patient cohorts.

Conclusion

As a higher expression of CHAC1 was observed in tissue cores with high Ki67 index and positive lymph node metastasis it may be concluded that enhanced CHAC1 expression correlates with proliferation and metastasis. The further analysis of breast cancer patients’ survival data through KM plot indicated that high CHAC1 expression is associated with a bad prognosis hinting that CHAC1 may have a possible prognostic significance in breast cancer.

Nur mit Berechtigung zugänglich

T Avril E Vauleon E Chevet 2017 Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers Oncogenesis 6 8 e373 https://doi.org/10.1038/oncsis.2017.72

Clarke HJ, Chambers JE, Liniker E, Marciniak SJ. Endoplasmic reticulum stress in malignancy. Cancer Cell. 2014;25(5):563–73. https://doi.org/10.1016/j.ccr.2014.03.015.CrossRefPubMed

Madden E, Logue SE, Healy SJ, Manie S, Samali A. The role of the unfolded protein response in cancer progression: from oncogenesis to chemoresistance. Biol Cell. 2019;111(1):1–17. https://doi.org/10.1111/boc.201800050.CrossRefPubMed

Chevet E, Hetz C, Samali A. Endoplasmic reticulum stress–activated cell reprogramming in oncogenesis. Cancer Discov. 2015;5(6):586–97. https://doi.org/10.1158/2159-8290.CD-14-1490.CrossRefPubMed

McGrath EP, Logue SE, Mnich K, Deegan S, Jäger R, Gorman AM, et al. The unfolded protein response in breast cancer. Cancers. 2018;10(10):344. https://doi.org/10.3390/cancers10100344.CrossRefPubMedCentral

Mungrue IN, Pagnon J, Kohannim O, Gargalovic PS, Lusis AJ. CHAC1/MGC4504 is a novel proapoptotic component of the unfolded protein response, downstream of the ATF4-ATF3-CHOP cascade. J Immunol. 2009;182(1):466–76. https://doi.org/10.4049/jimmunol.182.1.466.CrossRefPubMed

Kumar A, Tikoo S, Maity S, Sengupta S, Sengupta S, Kaur A, et al. Mammalian proapoptotic factor ChaC1 and its homologues function as γ-glutamyl cyclotransferases acting specifically on glutathione. EMBO Rep. 2012;13(12):1095–101. https://doi.org/10.1038/embor.2012.156.CrossRefPubMedPubMedCentral

Gargalovic PS, Imura M, Zhang B, Gharavi NM, Clark MJ, Pagnon J, et al. Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids. Proc Natl Acad Sci. 2006;103(34):12741–6. https://doi.org/10.1073/pnas.0605457103.CrossRefPubMedPubMedCentral

Perra L, Balloy V, Foussignière T, Moissenet D, Petat H, Mungrue IN, et al. CHAC1 is differentially expressed in normal and cystic fibrosis bronchial epithelial cells and regulates the inflammatory response induced by Pseudomonas aeruginosa. Front Immunol. 2018;9:2823. https://doi.org/10.3389/fimmu.2018.02823.CrossRefPubMedPubMedCentral

10.

Li S, Jia Y, Xue M, Hu F, Zheng Z, Zhang S, et al. Inhibiting Rab27a in renal tubular epithelial cells attenuates the inflammation of diabetic kidney disease through the miR-26a-5p/CHAC1/NF-kB pathway. Life Sci. 2020;261: 118347. https://doi.org/10.1016/j.lfs.2020.118347.CrossRefPubMed

11.

Chen M-S, Wang S-F, Hsu C-Y, Yin P-H, Yeh T-S, Lee H-C, et al. CHAC1 degradation of glutathione enhances cystine-starvation-induced necroptosis and ferroptosis in human triple negative breast cancer cells via the GCN2-eIF2α-ATF4 pathway. Oncotarget. 2017;8(70): 114588. https://doi.org/10.18632/oncotarget.23055.CrossRefPubMedPubMedCentral

12.

Wang N, Zeng G-Z, Yin J-L, Bian Z-X. Artesunate activates the ATF4-CHOP-CHAC1 pathway and affects ferroptosis in Burkitt’s Lymphoma. Biochem Biophys Res Commun. 2019;519(3):533–9. https://doi.org/10.1016/j.bbrc.2019.09.023.CrossRefPubMed

13.

Ogawa T, Wada Y, Takemura K, Board PG, Uchida K, Kitagaki K, et al. CHAC1 overexpression in human gastric parietal cells with Helicobacter pylori infection in the secretory canaliculi. Helicobacter. 2019;24(4): e12598. https://doi.org/10.1111/hel.12598.CrossRefPubMedPubMedCentral

14.

Wada Y, Takemura K, Tummala P, Uchida K, Kitagaki K, Furukawa A, et al. Helicobacter pylori induces somatic mutations in TP 53 via overexpression of CHAC 1 in infected gastric epithelial cells. FEBS Open Bio. 2018;8(4):671–9. https://doi.org/10.1002/2211-5463.12402.CrossRefPubMedPubMedCentral

15.

Liu Y, Li M, Shi D, Zhu Y. Higher expression of cation transport regulator-like protein 1 (CHAC1) predicts of poor outcomes in uveal melanoma (UM) patients. Int Opthalmol. 2019;39(12):2825–32. https://doi.org/10.1007/s10792-019-01129-1.CrossRef

16.

Stelzer Y, Yanuka O, Benvenisty N. Global analysis of parental imprinting in human parthenogenetic induced pluripotent stem cells. Nat Struct Biol. 2011;18(6):735. https://doi.org/10.1038/nsmb.2050.CrossRef

17.

Chen X, Iliopoulos D, Zhang Q, Tang Q, Greenblatt MB, Hatziapostolou M, et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway. Nature. 2014;508(7494):103–7. https://doi.org/10.1038/nature13119.CrossRefPubMedPubMedCentral

18.

Cook KL, Clarke R. Role of GRP78 in promoting therapeutic-resistant breast cancer. Future Med Chem. 2015;7(12):1529–34. https://doi.org/10.4155/FMC.15.80.CrossRefPubMedPubMedCentral

19.

Goebel G, Berger R, Strasak A, Egle D, Müller-Holzner E, Schmidt S, et al. Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients. Br J Cancer. 2012;106(1):189–98. https://doi.org/10.1038/bjc.2011.510.CrossRefPubMed

20.

Jahn B, Arvandi M, Rochau U, Fiegl H, Goebel G, Marth C, et al. Development of a novel prognostic score for breast cancer patients using mRNA expression of CHAC1. J Comp Eff Res. 2017;6(7):563–74. https://doi.org/10.2217/cer-2017-0015.CrossRefPubMed

21.

Chander H, Truesdell P, Meens J, Craig AW. Transducer of Cdc42-dependent actin assembly promotes breast cancer invasion and metastasis. Oncogene. 2013;32(25):3080–90. https://doi.org/10.1038/onc.2012.317.CrossRefPubMed

22.

Suman P, Mehta V, Craig AW, Chander H. Wild-type p53 suppresses formin-binding protein-17 (FBP17) to reduce invasion. Carcinogenesis. 2022;43(5):494–503. https://doi.org/10.1093/carcin/bgac015.CrossRefPubMed

23.

Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878. https://doi.org/10.1038/s41598-017-17204-5.CrossRefPubMedPubMedCentral

24.

Ramachandran P, Dobie R, Wilson-Kanamori J, Dora E, Henderson B, Luu N, et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature. 2019;575(7783):512–8. https://doi.org/10.1038/s41586-019-1631-3.CrossRefPubMedPubMedCentral

25.

Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123(3):725–31. https://doi.org/10.1007/s10549-009-0674-9.CrossRefPubMed

26.

Rivenbark AG, O’Connor SM, Coleman WB. Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. Am J Pathol. 2013;183(4):1113–24. https://doi.org/10.1016/j.ajpath.2013.08.002.CrossRefPubMedPubMedCentral

27.

Butti R, Das S, Gunasekaran VP, Yadav AS, Kumar D, Kundu GC. Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. Mol Cancer. 2018;17(1):34. https://doi.org/10.1186/s12943-018-0797-x.CrossRefPubMedPubMedCentral

28.

Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17(1):58. https://doi.org/10.1186/s12943-018-0782-4.CrossRefPubMedPubMedCentral

29.

Weigelt B, Ng CK, Shen R, Popova T, Schizas M, Natrajan R, et al. Metastatic breast carcinomas display genomic and transcriptomic heterogeneity. Mod Pathol. 2015;28(3):340–51. https://doi.org/10.1038/modpathol.2014.163.CrossRefPubMed

30.

Mehta V, Chander H, Munshi A. Complex roles of discoidin domain receptor tyrosine kinases in cancer. Clin TranslOncol. 2021;23(8):1497–1510. https://doi.org/10.1007/s12094-021-02552-6. CrossRef

31.

Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. The Breast. 2015;24:S26–35. https://doi.org/10.1016/j.breast.2015.07.008.CrossRefPubMed

32.

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736–50. https://doi.org/10.1093/jnci/djp082.CrossRefPubMedPubMedCentral

33.

Feeley LP, Mulligan AM, Pinnaduwage D, Bull SB, Andrulis IL. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information. Mod Pathol. 2014;27(4):554–61. https://doi.org/10.1038/modpathol.2013.153.CrossRefPubMed

34.

De Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Br J Cancer. 2007;96(10):1504–13. https://doi.org/10.1038/sj.bjc.6603756.CrossRefPubMedPubMedCentral

35.

Hashmi AA, Hashmi KA, Irfan M, Khan SM, Edhi MM, Ali JP, et al. Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters. BMC Res Notes. 2019;12(1):1–5. https://doi.org/10.1186/s13104-019-4653-x.CrossRef

36.

Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11(2):174–83. https://doi.org/10.1016/S1470-2045(09)70262-1.CrossRefPubMed

37.

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1-pl1. https://doi.org/10.1126/scisignal.2004088.

38.

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. AACR; 2012.

39.

Ji R-C. Lymph nodes and cancer metastasis: new perspectives on the role of intranodal lymphatic sinuses. Int J Mol Sci. 2017;18(1):51. https://doi.org/10.3390/ijms18010051.CrossRef

40.

Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer. 2002;2(8):573–83. https://doi.org/10.1038/nrc863.CrossRefPubMed

41.

Mehta V, Meena J, Kasana H, Munshi A, Chander H. Prognostic significance of CHAC1 expression in breast cancer. Mol Biol Rep. 2022:1–10. doi:https://doi.org/10.1007/s11033-022-07673-x

42.

Russnes HG, Navin N, Hicks J, Borresen-Dale A-L. Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest. 2011;121(10):3810–8. https://doi.org/10.1172/JCI57088.CrossRefPubMedPubMedCentral

43.

Kalinowski L, Saunus JM, Reed AEM, Lakhani SR. Breast Cancer Heterogeneity in Primary and Metastatic Disease. Breast Cancer Metastasis and Drug Resistance. Springer; 2019. p. 75–104.

44.

Riggio AI, Varley KE, Welm AL. The lingering mysteries of metastatic recurrence in breast cancer. Br J Cancer. 2020;124(1):1–14. https://doi.org/10.1038/s41416-020-01161-4.CrossRef

45.

Turashvili G, Brogi E. Tumor heterogeneity in breast cancer. Front Med. 2017;4:227. https://doi.org/10.3389/fmed.2017.00227.CrossRef

46.

Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell. 2010;140(1):62–73. https://doi.org/10.1016/j.cell.2009.12.007.CrossRefPubMed

47.

Kamdje AHN, Etet PFS, Vecchio L, Muller JM, Krampera M, Lukong KE. Signaling pathways in breast cancer: therapeutic targeting of the microenvironment. Cell Signal. 2014;26(12):2843–56. https://doi.org/10.1016/j.cellsig.2014.07.034.CrossRef

48.

Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev. 2012;38(6):698–707. https://doi.org/10.1016/j.ctrv.2011.11.005.CrossRefPubMed

49.

Scriven P, Coulson S, Haines R, Balasubramanian S, Cross S, Wyld L. Activation and clinical significance of the unfolded protein response in breast cancer. Br J Cancer. 2009;101(10):1692–8. https://doi.org/10.1038/sj.bjc.6605365.CrossRefPubMedPubMedCentral

50.

Suman P, Mishra S, Chander H. High formin binding protein 17 (FBP17) expression indicates poor differentiation and invasiveness of ductal carcinomas. Sci Rep. 2020;10(1):1–10. https://doi.org/10.1038/s41598-020-68454-9.CrossRef

51.

Giudici F, Petracci E, Nanni O, Bottin C, Pinamonti M, Zanconati F, et al. Elevated levels of eEF1A2 protein expression in triple negative breast cancer relate with poor prognosis. PLoS ONE. 2019;14(6): e0218030. https://doi.org/10.1371/journal.pone.0218030.CrossRefPubMedPubMedCentral

52.

Cerqueira OL, Truesdell P, Baldassarre T, Vilella-Arias SA, Watt K, Meens J, et al. CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis. Oncotarget. 2015;6(11):9397. https://doi.org/10.18632/oncotarget.3351.CrossRefPubMedPubMedCentral

53.

van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, et al. Neu-protein overexpression in breast cancer. N Engl J Med. 1988;319(19):1239–45. https://doi.org/10.1056/NEJM198811103191902.CrossRefPubMed

54.

Zhang K, Liu H, Song Z, Jiang Y, Kim H, Samavati L, et al. The UPR Transducer IRE1 promotes breast cancer malignancy by degrading tumor suppressor microRNAs. Iscience. 2020;23(9): 101503. https://doi.org/10.1016/j.isci.2020.101503.CrossRefPubMedPubMedCentral

55.

Li H, Chen X, Gao Y, Wu J, Zeng F, Song F. XBP1 induces snail expression to promote epithelial-to-mesenchymal transition and invasion of breast cancer cells. Cell Signal. 2015;27(1):82–9. https://doi.org/10.1016/j.cellsig.2014.09.018.CrossRefPubMed

56.

Pathmanathan N, Balleine RL. Ki67 and proliferation in breast cancer. J Clin Pathol. 2013;66(6):512–6. https://doi.org/10.1136/jclinpath-2012-201085.CrossRefPubMed

57.

van Diest PJ, van der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol. 2004;57(7):675–81. https://doi.org/10.1136/jcp.2003.010777.CrossRefPubMedPubMedCentral

58.

Gerashchenko TS, Novikov NM, Krakhmal NV, Zolotaryova SY, Zavyalova MV, Cherdyntseva NV, et al. Markers of cancer cell invasion: are they good enough? J Clin Med. 2019;8(8):1092. https://doi.org/10.3390/jcm8081092.CrossRefPubMedCentral

59.

Wu J, Wang X, Wang N, Ma L, Xie X, Zhang H, et al. Identification of novel antioxidant gene signature to predict the prognosis of patients with gastric cancer. World J Surg Oncol. 2021;19(1):1–11. https://doi.org/10.1186/s12957-021-02328-w.CrossRef

60.

Xiao R, Wang S, Guo J, Liu S, Ding A, Wang G, et al. Ferroptosis-related gene NOX4, CHAC1 and HIF1A are valid biomarkers for stomach adenocarcinoma. J Cell Mol Med. 2022. https://doi.org/10.1111/jcmm.17171.CrossRefPubMedPubMedCentral

61.

Hong Y, Lin M, Ou D, Huang Z, Shen P. A novel ferroptosis-related 12-gene signature predicts clinical prognosis and reveals immune relevancy in clear cell renal cell carcinoma. BMC Cancer. 2021;21(1):1–14. https://doi.org/10.1186/s12885-021-08559-0.CrossRef

62.

Tang W, Xu F, Zhao M, Zhang S. Ferroptosis regulators, especially SQLE, play an important role in prognosis, progression and immune environment of breast cancer. BMC Cancer. 2021;21(1):1–19. https://doi.org/10.1186/s12885-021-08892-4.CrossRef

63.

Liu C, Liu Y, Yu Y, Zhao Y, Yu A. Comprehensive analysis of ferroptosis-related genes and prognosis of cutaneous melanoma. BMC Med Genomics. 2022;15(1):1–17. https://doi.org/10.1186/s12920-022-01194-z.CrossRef

64.

Xu Z, Xie Y, Mao Y, Huang J, Mei X, Song J et al. Ferroptosis-related gene signature predicts the prognosis of skin cutaneous melanoma and response to immunotherapy. Front Genet. 2021;12. doi:https://doi.org/10.3389/fgene.2021.758981.

65.

Nguyen J, Tirla A, Rivera-Fuentes P. Disruption of mitochondrial redox homeostasis by enzymatic activation of a trialkylphosphine probe. Org Biomol Chem. 2021;19(12):2681–7. https://doi.org/10.1039/d0ob02259d.CrossRefPubMed

66.

Wang Z, Li M, Liu Y, Qiao Z, Bai T, Yang L, et al. Dihydroartemisinin triggers ferroptosis in primary liver cancer cells by promoting and unfolded protein response-induced upregulation of CHAC1 expression. Oncol Rep. 2021;46(5):1–14. https://doi.org/10.3892/or.2021.8191.CrossRef

67.

Li D, Liu S, Xu J, Chen L, Xu C, Chen F, et al. Ferroptosis-related gene CHAC1 is a valid indicator for the poor prognosis of kidney renal clear cell carcinoma. J Cell Mol Med. 2021;25(7):3610–21.CrossRef

Titel: High levels of unfolded protein response component CHAC1 associates with cancer progression signatures in malignant breast cancer tissues
verfasst von: Vikrant Mehta
Prabhat Suman
Harish Chander
Publikationsdatum: 05.08.2022
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 12/2022
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-022-02889-6

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

High levels of unfolded protein response component CHAC1 associates with cancer progression signatures in malignant breast cancer tissues

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2022

Diagnostic value of exosomes in patients with liver cancer: a systematic review

Significant position of C-myc in colorectal cancer: a promising therapeutic target

Synergistic effects of radiotherapy and targeted immunotherapy in improving tumor treatment efficacy: a review

Intraoperative radiotherapy versus no radiotherapy for early stage low-risk breast cancer patients undergoing breast-conserving surgery: a propensity score matching study based on the SEER database

Interaction between gut microbiota and tumour chemotherapy

Role of papillary thyroid carcinoma patients with Hashimoto thyroiditis: evaluation of oxidative stress and inflammatory markers

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie